====================
referred by Steve Jobs:  mass.robert@gene.com or at 650-255-7403. 

Bob Mass Genentech:

Meg Moony GI program at NCI -> he'll ping her on other phase I or II trials (from other companies)

had seen my lecture

what do you have in the pipeline?

sequencing my tumor?

RAS
K-RAS
mutations


herbotux


avastin?
	phase III trial -> no benefit
	bowel perforation


Genentech: parallelize search: grow cell and see what I'm sensitive to? -> 

targeted therapies -> looking at me specifically

we want: playbook 

spore grants: Johns Hopkins -> institutions that NCI recognizes

5 or 6 
angiogenesis: unique attribute of cancer: produce its own blood supply (pancreatic is very much that way)
disregulated growth signalling
disordered apoptosis : cells that don't have "suicide program" built in ==> WHAT THEY TARGET AT GENENTECH ==> induce cells to die ===> stuff in phase II
P-53 mutation: gatekeeper enzyeme: apoptosis regulator

took my tumor and stained it for some of these markers -> maybe in the future, an apoptosis agent should be higher/lower priority
     1) cold genomic expression profiling -> genomic expression profiling
     2) can look at other markers


high blood pressure in 20%

delayed

stroke/heart attack



257 in control 
0.4% in avastin 

avastin is more useful *earlier* in treatment -> if you're going to use it, use it *now*

hercepton breast cancer

avastin: vascular permeability

CT scan: gladamidium (contrast): make leaky areas turn white

"what other tests" (long shot: to determine if avastin was working...)
DCMRI: dynamic contrast MRI
       if you see a permeabilty change: gives us a sense of whether the tumor is angeogencially active
       marker K-Trans

CALL:
	regarding risks of avastin
	Hedy Kindler (avastin + tarceva) 773-702-0360 [Chicago] -- whipple influence ?
	Vince Picozzi (

how do we know if it's really benefiting you, and when do we stop?

